Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — ADPD 2024
11 slides from Ac Immune Sa's conference presentation, March 2024
Slide 1: ACI-35.030 anti-phospho Tau active immunotherapy produces antibodies that prevent pathological Tau seeding in vitro
ACI-35.030 anti-phospho Tau active immunotherapy produces antibodies that prevent pathological Tau seeding in vitro Marija Vukicevic, PhD | ADPD, March 2024 © 2024 AC Immune. Not to be used or reproduced without permission ADPD March 2024 © 2024 AC Immune. Not to be used or reproduced without permis
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include s
Slide 3: Active immunization for early intervention in Alzheimer's Disease
Active immunization for early intervention in Alzheimer’s Disease Preventing Tau spreading and disease progression Immunotherapy Hyperphosphorylated Tau aggregates in AD Cell-to-cell spread Healthy neuron Affected neuron ■ Tau: a validated target through ■ Antibodies are suggested to selectively Con
Slide 4: ACI-35.030: anti-pTau active immunotherapy
ACI-35.030: anti-pTau active immunotherapy Induces superior antibodies to fight Alzheimer’s disease ACI-35.030 Preclinical and Clinical Performances Immunogenicity against Generates a ++++ pTau species target-specific antibody response Specificity towards ++++1 pathological Tau species Sustainabilit
Slide 5: Immunogenicity of ACI-35.030 in non-human primates
Immunogenicity of ACI-35.030 in non-human primates Strong and sustained antibody response that matures towards the pathological target Anti-pTau peptide IgG titers Anti-pTau & anti-Tau peptide IgG titers Anti-ePHF IgG titers Concentration (Endpoint titer) Concentration (Endpoint titer) 1×10 6 1×10 6
Slide 6: Functionality of ACI-35.030-induced antibodies
Functionality of ACI-35.030-induced antibodies Can ACI-35.030-induced antibodies prevent seeding and intracellular Tau aggregation ? Assay principle: ▪ Assessment of capacity of ACI-35.030-induced antibodies to bind to and neutralize seeding capacity of ePHF, further decreasing formation of intracel
Slide 7: ACI-35.030 induces antibodies that prevent Tau seeding
ACI-35.030 induces antibodies that prevent Tau seeding Specific reduction of ePHF-seeded Tau aggregation using non-human primate immune sera * Seeding reduction (Mean of 5 NHPs per group) Serum dilution 50 1:100 Reduction in rat Tau p = 0.116 40 1:200 aggregates [%] ** 1:400 30 1:800 20 10 0 Placebo
Slide 8: Over time increase in prevention of Tau seeding
Over time increase in prevention of Tau seeding Increasing seeding prevention with subsequent immunizations in non-human primates Anti-ePHF IgG titers * Seeding reduction (Serum pool from 6 immunized NHPs) (Serum pool from 6 immunized NHPs) 10 6 80 Serum dilution Concentration in AU/mL Reduction in
Slide 9: ACI-35.030 anti-phospho Tau active immunotherapy
ACI-35.030 anti-phospho Tau active immunotherapy ▪ ACI-35.030 induces: ✓ strong and sustained antibody response ✓ maturation of the antibody response over time towards the pathological target ▪ ACI-35.030 induces antibodies in non-human primates with: ✓ capacity to specifically reduce ePHF-seeded de
Slide 10: Acknowledgements
Acknowledgements J&J Innovative Medicine Eva Gollwitzer Clara Theunis Emma Fiorini Bruno Vasconcelos Stefanie Siegert Liesje Naessens Stefania Rigotti Nathalie Chuard Fabiana Tione Laure Font Marie Kosco-Vilbois David Hickman Madiha Derouazi Andrea Pfeifer ADPD March 2024 © 2024 AC Immune. Not to be
Slide 11: AC Immune
AC Immune We continue to shape the future of neurodegeneration by discovering and developing breakthrough therapies through pioneering science and precision medicine Web: https://www.acimmune.com/ Social media: www.linkedin.com/company/ac-immune Business development: [email protected] Investors and Me